Mike I. Walton
Cancer Clinic(US)
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Ubiquitin and proteasome pathways, Cancer Mechanisms and Therapy, ATP Synthase and ATPases Research, DNA Repair Mechanisms
Most-Cited Works
- → Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises(2008)542 cited
- → The Cyclin-dependent Kinase Inhibitor CYC202 (R-Roscovitine) Inhibits Retinoblastoma Protein Phosphorylation, Causes Loss of Cyclin D1, and Activates the Mitogen-activated Protein Kinase Pathway(2004)193 cited
- → CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs(2012)92 cited
- → AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity(2012)91 cited
- → Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930(2010)86 cited
- → The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma(2015)68 cited
- → An evaluation of the ability of pifithrin-α and -β to inhibit p53 function in two wild-type p53 human tumor cell lines(2005)64 cited
- → AT7867 Is a Potent and Oral Inhibitor of AKT and p70 S6 Kinase That Induces Pharmacodynamic Changes and Inhibits Human Tumor Xenograft Growth(2010)62 cited
- → Characterisation of molecular events following cisplatin treatment of two curable ovarian cancer models: contrasting role for p53 induction and apoptosis in vivo(2004)20 cited
- → Preclinical pharmacology of CB30900, a novel dipeptide inhibitor of thymidylate synthase, in mice.(1996)5 cited